BioSpace News Archive

Today IntellaSphere, the leading Collaborative Marketing Platform and Business Marketing Cooperative provider, announced the launch of its Rise Above It program, to help small businesses rebuild sales.

The American Cancer Society would like to welcome Ellen McElligott to the Distinguished Partners team. She will help lead the Society’s North Central Region as Senior Director, Corporate Relations & Account Operations. Prior to j

-Single doses of TERN-201 were safe and well tolerated and demonstrated potent, selective, and sustained inhibition of SSAO in a Phase 1 clinical trial, with near complete inhibition of plasma SSAO activity observed- -TERN-501 demonstrated potent and selective THR-β agonism, and significantly reduced liver steatosis, fibrosis, and serum markers of liver damage in NASH preclinical rodent models- FOSTER CITY, Calif.--( BUSINESS WIRE )-- Terns Ph

Temporary Urgent Public Health Need Site also authorized in Toronto shelter to help reduce overdoses during COVID-19

Conversion Labs, Inc., a direct-to-consumer telemedicine and wellness company, has been invited to present at LD Micro 500 virtual institutional investor conference being held on September 1-4, 2020.

Recognizing the need for technologies to help advance the response and recovery to the COVID-19 pandemic, KPMG LLP has built the technology architecture for a solution that can match patients in clinical trials for convalescent plasma therapy to recovered patients willing to donate their antibodies.

Millions of patients rely on the nation’s emergency physicians to help them through life’s worst moments.

Dr. Rama Kondru, executive vice president, chief information officer and chief technology officer at Medidata, a Dassault Systèmes company, has been selected by PharmaVOICE magazine as one of 2020’s 100 Most Inspiring People in the life science industry.

Nanodropper, Inc., a medical device company offering a first-of-its-kind eyedrop bottle adaptor that reduces eyedrop size, has been named the recipient of a Phase II Small Business Innovation Research contract with the United States Air Force.

miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary RNA-targeted therapies with a specific focus on microRNAs, today announced that the company held a Type C meeting with the FDA Office of Oncologic Diseases on August 11, 2020 to discuss miRagen’s future clinical development plans for cobomarsen for the potential treatment of Adult T-Cell Leukemia/Lymphom